Jain, Rohil
Ajenu, Emmanuella O.
Lopera Higuita, Manuela
Hafiz, Ehab O. A.
Muzikansky, Alona
Romfh, Padraic
Tessier, Shannon N.
Funding for this research was provided by:
Massachusetts General Hospital (Fund for Medical Discovery Award, Executive Committee for Research)
American Association for the Study of Liver Diseases (LIFER23-263034)
National Institutes of Health (R01DK134590)
Article History
Received: 11 December 2023
Accepted: 21 March 2024
First Online: 27 March 2024
Competing interests
: The authors declare competing interests. Dr. Tessier and Mr. Romfh have provisional patent applications relevant to this study. P.R. is an employee and shareholder of Pendar Technologies. S.N.T.’s competing interests are managed by the MGH and Partners HealthCare in accordance with their conflict-of-interest policies, and P. R.’s competing interests are subject to the Research Integrity Policy of Pendar Technologies. The following patented technologies have been used in this study: US2020/0281474A1 In-vivo monitoring of cellular energetics with Raman spectroscopy (application). Additional patent applications for use in ophthalmology, tissue viability, and burn injury assessment using Resonance Raman Spectroscopy have been submitted where R.J. is also an inventor. This does not alter our adherence to Scientific Reports’ policies on sharing data and materials. All other authors do not have competing interests.